Livforsakringsbolaget Skandia Omsesidigt lowered its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 41.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,972 shares of the biopharmaceutical company’s stock after selling 1,400 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Alexion Pharmaceuticals were worth $274,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently modified their holdings of the stock. Robeco Institutional Asset Management B.V. increased its position in shares of Alexion Pharmaceuticals by 173.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 43,499 shares of the biopharmaceutical company’s stock valued at $6,047,000 after buying an additional 27,589 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of Alexion Pharmaceuticals by 63.6% in the third quarter. First Trust Advisors LP now owns 884,257 shares of the biopharmaceutical company’s stock worth $122,921,000 after acquiring an additional 343,838 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Alexion Pharmaceuticals by 146.8% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 36,237 shares of the biopharmaceutical company’s stock worth $5,037,000 after acquiring an additional 21,555 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Alexion Pharmaceuticals by 45.5% in the third quarter. Handelsbanken Fonder AB now owns 67,200 shares of the biopharmaceutical company’s stock worth $9,341,000 after acquiring an additional 21,000 shares during the last quarter. Finally, Calamos Advisors LLC boosted its stake in shares of Alexion Pharmaceuticals by 4.8% in the third quarter. Calamos Advisors LLC now owns 716,279 shares of the biopharmaceutical company’s stock worth $99,570,000 after acquiring an additional 32,533 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.
Shares of Alexion Pharmaceuticals stock traded down $1.62 during trading hours on Friday, hitting $125.56. The company’s stock had a trading volume of 156,684 shares, compared to its average volume of 1,890,150. The company has a quick ratio of 2.74, a current ratio of 3.16 and a debt-to-equity ratio of 0.32. The firm has a market cap of $27.49 billion, a PE ratio of 24.33, a price-to-earnings-growth ratio of 1.06 and a beta of 0.99. Alexion Pharmaceuticals, Inc. has a twelve month low of $102.10 and a twelve month high of $140.77.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.74 by $0.28. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.02 billion. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The company’s quarterly revenue was up 19.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.44 EPS. As a group, equities analysts expect that Alexion Pharmaceuticals, Inc. will post 6.82 earnings per share for the current year.
A number of analysts have recently issued reports on the company. ValuEngine raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 12th. BidaskClub lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 9th. Evercore ISI reissued an “outperform” rating and set a $158.00 price objective on shares of Alexion Pharmaceuticals in a research note on Thursday, July 26th. Jefferies Financial Group reissued a “hold” rating and set a $123.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, July 27th. Finally, Stifel Nicolaus lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $154.00 to $130.00 in a research note on Tuesday, August 7th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $161.29.
TRADEMARK VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Shares Sold by Livforsakringsbolaget Skandia Omsesidigt” was published by Fairfield Current and is the sole property of of Fairfield Current. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.fairfieldcurrent.com/2018/11/09/livforsakringsbolaget-skandia-omsesidigt-has-274000-position-in-alexion-pharmaceuticals-inc-alxn.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Recommended Story: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Alexion Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.